AD1
AD1 Holdings Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
AD1 Holdings Ltd. provides an on-line database and search platform to link employers and job candidates. The company is headquartered in Hawthorn, Victoria. The company went IPO on 2016-06-23. The firm is focused on providing and delivering software services and technology platforms to its customers, and other related supporting and consulting services. The firm operates in two verticals: HR Services and Niche Services. Under HR services, it provides software-as-a-service (SaaS) solutions in talent recruitment, employer value propositions in the form of ApplyDirect and Jobtale and mentoring products and services under the Art of Mentoring (AoM) banner. ApplyDirect provides customer-branded recruitment marketing platforms and related digital services. AoM provides mentoring programs that empower organizations to shift culture and develop their people. The company also operates Utility Software Solutions (USS), which specializes in SaaS-hosted customer interface solutions (CIS) and business process outsourcing (BPO) services for energy providers.
📈 Performance
Price History
-97.50%
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in AD1
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in AD1
742 days
AD1 investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in AD1 also invest in...
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
📊 Share price
$12.45 AUD
NULL GLOBAL
NULL SMART BETA
NULL ETHICAL
NULL EX AUSTRALIA
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
📊 Share price
$29.97 AUD
NULL GLOBAL
NULL SMART BETA
NULL ETHICAL
NULL THEMATIC
DHHF.AX was created on 2019-12-03 by BetaShares. The fund's investment portfolio concentrates primarily on target outcome asset allocation. DHHF.AX aims to provide exposure to a low-cost, multi-asset class portfolio with high growth potential, for investors with a high tolerance for risk. DHHF.AX targets an allocation of 90% growth assets (shares and listed property), 10% defensive assets (bonds and cash).
📊 Share price
$29.19 AUD
DZZF.AX was created on 2019-12-10 by BetaShares. The fund's investment portfolio concentrates primarily on target risk asset allocation. DZZF.AX aims to provide access to a cost-effective, true-to-label multi-asset ethical portfolio that offers high growth potential over the long term.
📊 Share price
$26.05 AUD
NULL GLOBAL
NULL ETHICAL
NULL THEMATIC
NULL SUSTAINABLE
GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index.
📊 Share price
$27.88 AUD
NULL AUSTRALIA
NULL SMART BETA
NULL ETHICAL
NULL THEMATIC
Want more shares? Try these...
Audinate Group Ltd. engages in the development and commercialization of audio visual software and hardware. Its principal activity is the development and sale of digital AV networking solutions. Its products include Dante AVIO adapters, software, Dante-enabled products, solutions for manufacturers and solutions for software developers. Dante is a technology platform that distributes digital audio and video signals over computer networks. Dante comprises software and chips, cards and modules that are sold to and integrated inside the AV products of its original equipment manufacturer (OEM) customers. The company also provides a series of products and services for AV professionals, including AVIO adapters and management and control software. Dante replaces all of those connections with a computer network, sending video or hundreds of channels of audio over slender ethernet cables with digital fidelity. Dante is available in over 3,500 products from more than 500 manufacturers.
📊 Share price
$9.61 AUD
NULL TECH
Adacel Technologies Ltd. develops and sells simulation and software applications and services. The company is headquartered in Melbourne, Victoria. The firm operates through two segments: Systems and Services. The Systems segment includes the sales of integrated software systems and products covering operational air traffic management as well as simulation and training applications. This segment also includes hardware and software sales. The Services segment is engaged in providing software maintenance and all aspects of system support, field services, and on-site technical services. Its customers include international air navigation service providers (ANSPs), military, defense and security organizations, universities, and airport authorities. Its REVAL virtual Air Traffic Control (ATC) tower system delivers a range of digital tower operational solutions, from consulting services to system design, development, deployment, and support.
📊 Share price
$0.62 AUD
Acumentis Group Ltd. engages in the provision of valuation, research, and advisory services in relation to property and businesses. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-05. The firm provides commercial and residential valuations, research, and property advice to various homeowners, investors, developers, and lenders. The company offers property valuation, insurance valuation, and advisory services to clients, including banks and financial institutions, property developers, property trusts, government, lawyers, accountants, real estate agents and independent retailers. Its services include property valuation, property advisory, quantity surveying, acquisition and compensation, capital gains tax, family law and legal, fund forecasts, illicit substance screening, insurance valuation, litigation and legal advisory services, property buyers agencies, self-managed super fund (SMSF) property valuation, stamp duty assessments, tax depreciation schedules and tenant representation. The company serves property classes such as residential, commercial, rural, agribusiness and government portfolios.
📊 Share price
$0.07 AUD
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
📊 Share price